Skip to main content

Table 3 Factors associated with SACT initiation and OS outcomes in patients diagnosed with stage IIIB–IV NSCLC in 2015–2016

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

  Patient characteristics, n (%) Factors associated with SACT initiationa Factors associated with OS in SACT-treated patientsb
Overall SACT untreated SACT treated
Parameter N = 392 n = 95 n = 297 Adjusted OR (95% CI) Overall P value Adjusted HR (95% CI) Overall
P value
Age at NSCLC diagnosis in years      0.059   0.024
  < 65 190 (48.5) 36 (37.9) 154 (51.9) 1.00 (ref) 1.00 (ref)
 65–74 118 (30.1) 26 (27.4) 92 (31.0) 0.85 (0.48–1.52) 1.42 (1.02–1.96)
  ≥ 75 84 (21.4) 33 (34.7) 51 (17.2) 0.33 (0.18–0.59) 1.60 (1.09–2.37)
Sex      0.234   0.060
 Male 303 (77.3) 75 (78.9) 228 (76.8) 1.00 (ref) 1.00 (ref)
 Female 89 (22.7) 20 (21.1) 69 (23.2) 1.45 (0.79–2.65) 0.68 (0.46–1.02)
TNM stage and brain metastasis at diagnosis      0.001   <  0.001
 Stage IIIB 54 (13.8) 7 (7.4) 47 (15.8) 1.00 (ref) 1.00 (ref)
 Stage IV without brain metastases 274 (69.9) 70 (73.7) 204 (68.7) 0.41 (0.17–0.99) 1.49 (0.96–2.33)
 Stage IV with brain metastases 64 (16.3) 18 (18.9) 46 (15.5) 0.29 (0.11–0.81) 2.93 (1.70–5.07)
Histology and mutations/rearrangements      0.401   0.001
 NSQ 289 (73.7) 68 (71.6) 221 (74.4) 1.00 (ref)
 NSQ EGFR/ALK wildtype 147 (49.5) 1.00 (ref)
 NSQ EGFR or ALK mutations/rearrangements 60 (20.2) 0.68 (0.44–1.06)
 NSQ EGFR/ALK not tested 14 (4.7) 0.96 (0.46–1.99)
 SQ 83 (21.2) 20 (21.1) 63 (21.2) 0.86 (0.46–1.60) 1.32 (0.90–1.93)
 NSCLC NOS/Others 20 (5.1) 7 (7.4) 13 (4.4) 0.51 (0.19–1.39) 3.08 (1.62–5.85)
  1. SACT systemic anti-cancer therapy, OS overall survival, NSCLC non-small cell lung cancer, OR odds ratio, CI confidence interval, HR hazard ratio, ref reference category, TNM tumour, node, and metastasis, NSQ non-squamous cell carcinoma, EGFR epidermal growth factor receptor gene, ALK anaplastic lymphoma kinase gene, SQ squamous cell carcinoma, NOS not otherwise specified
  2. a Multivariate logistic regression model; an OR < 1 indicates patients were less likely to receive SACT than the reference and an OR > 1 indicates more likely to receive SACT than the reference
  3. b Multivariate Cox model; survival within 2 years of diagnosis; an HR < 1 indicates better OS than the reference and an HR > 1 indicates a worse OS than the reference